Summary
7.32 0.01(0.14%)10/04/2024
Pulmonx Corp (LUNG)
Pulmonx Corp (LUNG)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.14 | -11.70 | 10.91 | 12.79 | -6.87 | -24.30 | 0.00 | -81.38 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.32 | |
| Open | 7.47 | |
| High | 7.47 | |
| Low | 7.26 | |
| Volume | 61,594 | |
| Change | 0.01 | |
| Change % | 0.14 | |
| Avg Volume (20 Days) | 173,949 | |
| Volume/Avg Volume (20 Days) Ratio | 0.35 | |
| 52 Week Range | 5.46 - 14.84 | |
| Price vs 52 Week High | -50.67% | |
| Price vs 52 Week Low | 34.07% | |
| Range | -2.01 | |
| Gap Up/Down | 0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 323 | |
| EBIDTA | -4,102,358 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 54.33 | |
| Book Value | 5.5090 | |
| Earnings Per Share | -1.2670 | |
| EPS Estimate Current Quarter | -0.3700 | |
| EPS Estimate Next Quarter | -0.3700 | |
| EPS Estimate Current Year | -1.3500 | |
| EPS Estimate Next Year | -1.2300 | |
| Diluted EPS (TTM) | -1.2670 | |
| Revenues | ||
| Profit Marging | -1.0093 | |
| Operating Marging (TTM) | -0.9945 | |
| Return on asset (TTM) | -0.1741 | |
| Return on equity (TTM) | -0.4417 | |
| Revenue TTM | 44,538,000 | |
| Revenue per share TTM | 1.2550 | |
| Quarterly Revenue Growth (YOY) | 0.2500 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 21,202,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 28.3286 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.1716 | |
| Revenue Enterprise Value | 24.2199 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 36,838,700 | |
| Shares Float | 31,483,825 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 8.37 | |
| Institutions (%) | 97.61 | |
09/09 16:05 EST - globenewswire.com
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV-
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV-
09/09 09:00 EST - prnewswire.com
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif. , Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at the 2024 World Conference on Lung Cancer (WCLC) in San Diego.
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif. , Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at the 2024 World Conference on Lung Cancer (WCLC) in San Diego.
08/29 16:05 EST - globenewswire.com
Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024.
Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024.
08/22 16:05 EST - globenewswire.com
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET.
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET.
07/31 22:33 EST - seekingalpha.com
Pulmonx Corporation (LUNG) Q2 2024 Earnings Call Transcript
Pulmonx Corporation (NASDAQ:LUNG ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler John Young - Canaccord Frank Takkinen - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Pulmonx Second Quarter 2024 Earnings Conference Call.
Pulmonx Corporation (LUNG) Q2 2024 Earnings Call Transcript
Pulmonx Corporation (NASDAQ:LUNG ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler John Young - Canaccord Frank Takkinen - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Pulmonx Second Quarter 2024 Earnings Conference Call.
07/31 18:51 EST - zacks.com
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago.
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago.
07/31 16:05 EST - globenewswire.com
Pulmonx Reports Second Quarter 2024 Financial Results
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024.
Pulmonx Reports Second Quarter 2024 Financial Results
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024.
07/29 16:05 EST - globenewswire.com
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston. Management is scheduled to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET.
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston. Management is scheduled to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET.
07/21 09:00 EST - seekingalpha.com
Pulmonx: Low Bar For Q2 Earnings
New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses.
Pulmonx: Low Bar For Q2 Earnings
New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses.
07/10 16:05 EST - globenewswire.com
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, July 31, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, July 31, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
06/24 09:20 EST - zacks.com
5 Medical Info Systems Stock to Buy for a Stable Portfolio
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
5 Medical Info Systems Stock to Buy for a Stable Portfolio
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
05/22 10:56 EST - zacks.com
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
05/16 18:46 EST - prnewswire.com
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif.
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif.
05/10 09:31 EST - zacks.com
5 Medical Info Systems Stocks to Buy for Stable Returns
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
5 Medical Info Systems Stocks to Buy for Stable Returns
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
05/06 17:03 EST - globenewswire.com
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”) granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on May 6, 2024 to Mehul Joshi in connection with his appointment as the Chief Financial Officer of Pulmonx in April 2024.
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”) granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on May 6, 2024 to Mehul Joshi in connection with his appointment as the Chief Financial Officer of Pulmonx in April 2024.
05/06 10:56 EST - zacks.com
Wall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High?
The consensus price target hints at a 56.1% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High?
The consensus price target hints at a 56.1% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
05/01 21:08 EST - seekingalpha.com
Pulmonx Corporation (LUNG) Q1 2024 Earnings Call Transcript
Pulmonx Corporation (NASDAQ:LUNG ) Q1 2024 Earnings Call Transcript May 1, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations at the Gilmartin Group Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jon Young - Canaccord Rick Wise - Stifel Vik Chopra - Wells Fargo Operator Good day, and thank you for standing by. Welcome to Pulmonx Q1 2024 Earnings Conference Call.
Pulmonx Corporation (LUNG) Q1 2024 Earnings Call Transcript
Pulmonx Corporation (NASDAQ:LUNG ) Q1 2024 Earnings Call Transcript May 1, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations at the Gilmartin Group Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jon Young - Canaccord Rick Wise - Stifel Vik Chopra - Wells Fargo Operator Good day, and thank you for standing by. Welcome to Pulmonx Q1 2024 Earnings Conference Call.
05/01 19:05 EST - zacks.com
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.42 per share a year ago.
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.42 per share a year ago.
05/01 16:05 EST - globenewswire.com
Pulmonx Reports First Quarter 2024 Financial Results
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the quarter ended March 31, 2024.
Pulmonx Reports First Quarter 2024 Financial Results
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the quarter ended March 31, 2024.
04/10 16:05 EST - globenewswire.com
Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024
REDWOOD CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 1, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024
REDWOOD CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 1, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.